{
    "Clinical Trial ID": "NCT00633464",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ixabepilone 40 mg/m^2",
        "  ixabepilone 40 mg/m^2 every 3 weeks",
        "INTERVENTION 2: ",
        "  Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2",
        "  cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Female subjects with triple negative (ER, PR, and HER2 negative) locally advanced non-resectable and/or metastatic breast cancer",
        "  Prior adjuvant or neoadjuvant anthracycline-based chemotherapy",
        "Exclusion Criteria:",
        "  Tumors that are fluorescence in situ hybridization test (FISH) positive or immunohistochemistry (IHC) 3+",
        "  Neuropathy > Grade 1",
        "  Prior systemic therapy for metastatic disease"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])",
        "  The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method.",
        "  Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks)",
        "Results 1: ",
        "  Arm/Group Title: Ixabepilone 40 mg/m^2",
        "  Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks",
        "  Overall Number of Participants Analyzed: 40",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  30.0        (16.6 to 46.5)",
        "Results 2: ",
        "  Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2",
        "  Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks",
        "  Overall Number of Participants Analyzed: 39",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  35.9        (21.2 to 52.8)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 9/40 (22.50%)",
        "  FEBRILE NEUTROPENIA 0/40 (0.00%)",
        "  NEUTROPENIA 0/40 (0.00%)",
        "  TACHYCARDIA 0/40 (0.00%)",
        "  SINUS ARRHYTHMIA 1/40 (2.50%)",
        "  STOMATITIS 0/40 (0.00%)",
        "  VOMITING 1/40 (2.50%)",
        "  ABDOMINAL PAIN 0/40 (0.00%)",
        "  RECTAL HAEMORRHAGE 0/40 (0.00%)",
        "  GASTROINTESTINAL HAEMORRHAGE 1/40 (2.50%)",
        "  DIARRHOEA 0/40 (0.00%)",
        "  PYREXIA 2/40 (5.00%)",
        "  CHEST PAIN 0/40 (0.00%)",
        "Adverse Events 2:",
        "  Total: 12/37 (32.43%)",
        "  FEBRILE NEUTROPENIA 2/37 (5.41%)",
        "  NEUTROPENIA 2/37 (5.41%)",
        "  TACHYCARDIA 2/37 (5.41%)",
        "  SINUS ARRHYTHMIA 0/37 (0.00%)",
        "  STOMATITIS 1/37 (2.70%)",
        "  VOMITING 1/37 (2.70%)",
        "  ABDOMINAL PAIN 1/37 (2.70%)",
        "  RECTAL HAEMORRHAGE 1/37 (2.70%)",
        "  GASTROINTESTINAL HAEMORRHAGE 0/37 (0.00%)",
        "  DIARRHOEA 1/37 (2.70%)",
        "  PYREXIA 0/37 (0.00%)",
        "  CHEST PAIN 1/37 (2.70%)"
    ]
}